Browse

(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study

DC Field Value Language
dc.contributor.authorLambert, Bieke-
dc.contributor.authorBacher, Klaus-
dc.contributor.authorDefreyne, Luc-
dc.contributor.authorVan Vlierberghe, Hans-
dc.contributor.authorJeong, Jae Min-
dc.contributor.authorWang, Rong Fu-
dc.contributor.authorvan Meerbeeck, Jan-
dc.contributor.authorSmeets, Peter-
dc.contributor.authorTroisi, Roberto-
dc.contributor.authorThierens, Hubert-
dc.contributor.authorDe Vos, Filip-
dc.contributor.authorVan de Wiele, Christophe-
dc.date.accessioned2009-12-31T02:32:02Z-
dc.date.available2009-12-31T02:32:02Z-
dc.date.issued2005-12-08-
dc.identifier.citationEur J Nucl Med Mol Imaging. 2006 Mar;33(3):344-52. Epub 2005 Dec 7.en
dc.identifier.issn1619-7070 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16333675-
dc.identifier.urihttps://hdl.handle.net/10371/24089-
dc.description.abstractPURPOSE: The aim of this study was to investigate the feasibility of administering increasing activities of (188)Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/lipiodo l ((188)Re-HDD/lipiodol) for the treatment of hepatocellular carcinoma (HCC) in patients with well-compensated cirrhosis.METHODS: The activity levels were increased by 1.1 GBq/step after a 6-week interval without unacceptable adverse events in at least five consecutive patients. Absorbed doses to the various organs were calculated according to the MIRD formalism, based on three gamma-scintigraphic studies. Response was assessed by means of MRI and alpha-fetoprotein (AFP) monitoring.RESULTS: Thirty-five treatments were carried out in 28 patients. Activities from 4.8 to 7.0 GBq (188)Re-HDD/lipiodol were administered via a transfemoral catheter. The mean absorbed dose to the liver (including tumour) was 7.6+/-2.2, 9.8+/-4.9 and 15.2+/-4.9 Gy for the 4.8-, 5.9- and 7.0-GBq groups, respectively. Treatment was well tolerated at all activity levels. Further escalation of the administered activity was not feasible owing to limitations related to the radiolabelling procedure. Response assessment on MRI showed partial response, stable disease and disease progression in 1, 28 and 2 assessable treatments, respectively. In 8 of 17 treatment sessions with an initially elevated AFP, a reduction ranging from 19% to 97% was observed 6 weeks later.CONCLUSION: Following the intra-arterial administration of 4.8-7.0 GBq (188)Re-HDD/lipiodol in patients with HCC and well-compensated liver cirrhosis, no severe adverse events occurred. Further escalation was not feasible owing to limitations in the radiolabelling procedure.en
dc.language.isoen-
dc.publisherSpringer Verlagen
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectCarcinoma, Hepatocellular/*metabolism/*radiotherapyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDose-Response Relationship, Radiationen
dc.subjectDrug Administration Scheduleen
dc.subjectFeasibility Studiesen
dc.subjectHalf-Lifeen
dc.subjectHumansen
dc.subjectIodized Oil/*pharmacokinetics/*therapeutic useen
dc.subjectLiver Neoplasms/*metabolism/*radiotherapyen
dc.subjectMetabolic Clearance Rateen
dc.subjectMiddle Ageden
dc.subjectOrgan Specificityen
dc.subjectOrganometallic Compounds/*pharmacokinetics/*therapeutic useen
dc.subjectRadiation Dosageen
dc.subjectRadiopharmaceuticals/adverse effects/pharmacokinetics/therapeutic useen
dc.subjectTissue Distributionen
dc.subjectTreatment Outcomeen
dc.subjectWhole-Body Countingen
dc.title(188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation studyen
dc.typeArticleen
dc.contributor.AlternativeAuthor정재민-
dc.identifier.doi10.1007/s00259-005-1954-1-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Nuclear Medicine (핵의학전공)Journal Papers (저널논문_핵의학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse